Villejuif, Ile-de-France, France · On-site
<p>Nous recherchons un(e) <strong>Technicien(ne), Chemical Development</strong> rigoureux(se) et passionné(e) par l'innovation scientifique pour contribuer au développement des méthodes analytiques qui accompagneront la …
Skills: Physico-chemical Characterization, Good Laboratory Practices (GLP), Analytical Method Development, Inorganic Chemistry, Pharmaceutical Quality Environment
Paris, Ile-de-France, France · On-site
<p>Nous recherchons un(e) Process Development Senior Manager autonome pour poursuivre la recherche et la production de nanoparticules qui pourront aider des millions de patients à travers le monde. Notre recherche innova…
Skills: Process Development, Process Engineering, Design of Experiments (DoE), Quality by Design (QbD), Scale-up
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
Develop and validate analytical methods, primarily in inorganic chemistry, to support the creation of nanoparticles for cancer treatment. Perform physico-chemical analyses on laboratory and clinical batches while ensuring strict documentation and quality compliance.
Requires a degree in Chemistry or a related scientific field with at least 5 years of experience in an analytical laboratory, ideally within pharma or biotech. Proficiency in physico-chemical characterization and knowledge of GLP are essential.
Nous recherchons un(e) Technicien(ne), Chemical Development rigoureux(se) et passionné(e) par l'innovation scientifique pour contribuer au développement des méthodes analytiques qui accompagneront la mise au point de nanoparticules destinées à améliorer le traitement de millions de patients atteints de cancer.
Notre recherche innovante est en plein développement et offre une opportunité unique de participer à des projets à la frontière entre la chimie, la nanotechnologie et le développement pharmaceutique.
Depuis notre création, notre équipe s'est engagée dans le développement de technologies disruptives en nanomédecine qui pourraient transformer durablement la prise en charge de nombreux cancers.
Nanobiotix conçoit et développe des nanoparticules qui améliorent en toute sécurité l'efficacité de la radiothérapie. Nous croyons que la radiothérapie associée au NBTXR3 peut devenir une nouvelle référence dans le traitement du cancer.
Ces compétences représentent un idéal pour le poste, mais notre processus de recrutement est inclusif et ouvert à la diversité des parcours et des expériences.
Nanobiotix propose une rémunération fixe et variable, ainsi que divers avantages tels qu'une mutuelle, une prévoyance, un plan d'épargne retraite, des titres-restaurant et des indemnités de transport.
Building new therapies atom by atom.
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanotherapeutics company pioneering new approaches to significantly improve patient outcomes for millions around the world by building new therapies atom by atom. The Nanobiotix philosophy is one rooted in designing pioneer physical-based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges. The Nanobiotix global development strategy seeks to address the largest market in oncology—patients who receive radiotherapy as part of their treatment—with NBTXR3 (JNJ-1900). As the first product candidate from the company’s nanoradioenhancer platform, NBTXR3 aims to increase the tumor-killing effect of radiotherapy without increasing damage to surrounding healthy tissues and synergize with other anti-cancer therapies such as immune checkpoint inhibitors. Beyond NBTXR3, the Curadigm Nanoprimer Platform represents the second technology platform from Nanobiotix and the company’s next lever for growth. Curadigm's innovative approach seeks to improve treatment outcomes across several therapeutic classes by optimizing drug bioavailability and efficacy through systemic delivery enhancement. Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA. More: www.nanobiotix.com Read our Social Media Community Guidelines: https://nanobiotix.com/social-community-guidelines/
Offices: 60, rue de Wattignies, Bat C, PARIS, 75012, FR
Building new therapies atom by atom.
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanotherapeutics company pioneering new approaches to significantly improve patient outcomes for millions around the world by building new therapies atom by atom. The Nanobiotix philosophy is one rooted in designing pioneer physical-based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges. The Nanobiotix global development strategy seeks to address the largest market in oncology—patients who receive radiotherapy as part of their treatment—with NBTXR3 (JNJ-1900). As the first product candidate from the company’s nanoradioenhancer platform, NBTXR3 aims to increase the tumor-killing effect of radiotherapy without increasing damage to surrounding healthy tissues and synergize with other anti-cancer therapies such as immune checkpoint inhibitors. Beyond NBTXR3, the Curadigm Nanoprimer Platform represents the second technology platform from Nanobiotix and the company’s next lever for growth. Curadigm's innovative approach seeks to improve treatment outcomes across several therapeutic classes by optimizing drug bioavailability and efficacy through systemic delivery enhancement. Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA. More: www.nanobiotix.com Read our Social Media Community Guidelines: https://nanobiotix.com/social-community-guidelines/
Offices: 60, rue de Wattignies, Bat C, PARIS, 75012, FR
